Hepatitis B virus-human immunodeficiency virus co-infection in France: a cross-sectional multicentre study

SUMMARY This prospective, multicentre study was conducted between September and October 2003 in 38 French departments of internal medicine, infectious disease and hepatogastroenterology and included 406 consecutive HBV-infected patients (positive HBsAg), half of whom were HIV-infected (53 %). The aim was to outline the main characteristics of hepatitis B virus (HBV)-human immunodeficiency virus (HIV) co-infected patients in French hospitals. HBV-HIV co-infected patients (85 % were receiving HAART ; mean CD4 count 447i245/ml, HIV RNA load <400 copies/ml, 67 % of patients), compared to HIV-negative patients, were more often male, injecting drug users, HBeAg-positive and HCV-HIV co-infected (P<10 x4 ). They underwent liver biopsy less often (31 % vs .5 1 %,P<10 x4 ), particularly those with severe immunodeficiency. They received anti-HBV treatment more often (75 % vs .4 5 . 7% ,P<10 x4 ), mainly lamivudine and tenofovir. Significant improvements in the management of such patients are awaited mainly in the appraisal of liver disease by either liver biopsy or non-invasive alternatives to liver biopsy.